Aligos Therapeutics to Present at Investor Conferences in December
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced its participation in two major investor conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference at 11:00am ET and the Evercore ISI 7th Annual HealthCONx Conference at 4:15pm ET, both on December 3, 2024.
Management will conduct fireside chats at both events and participate in one-on-one meetings. The presentations will be webcast live on the company's investor relations website, with replays available for at least 30 days afterward.
Aligos Therapeutics (Nasdaq: ALGS), un'azienda biofarmaceutica in fase clinica specializzata in malattie del fegato e virali, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. L'azienda si presenterà alla Piper Sandler 36th Annual Healthcare Conference alle 11:00 ET e alla Evercore ISI 7th Annual HealthCONx Conference alle 16:15 ET, entrambe il 3 dicembre 2024.
Il management condurrà chat informali in entrambi gli eventi e parteciperà a incontri one-to-one. Le presentazioni saranno trasmesse in diretta sul sito web delle relazioni con gli investitori dell'azienda, con la possibilità di rivederle per almeno 30 giorni dopo.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biofarmacéutica en etapa clínica especializada en enfermedades hepáticas y virales, ha anunciado su participación en dos importantes conferencias de inversores este diciembre. La empresa presentará en la Piper Sandler 36th Annual Healthcare Conference a las 11:00 a.m. ET y en la Evercore ISI 7th Annual HealthCONx Conference a las 4:15 p.m. ET, ambas el 3 de diciembre de 2024.
La dirección llevará a cabo charlas informales en ambos eventos y participará en reuniones uno a uno. Las presentaciones se transmitirán en vivo en el sitio web de relaciones con inversores de la empresa, con repeticiones disponibles durante al menos 30 días después.
Aligos Therapeutics (Nasdaq: ALGS) 는 간 및 바이러스 질환을 전문으로 하는 임상 단계의 생명공학 회사로, 이번 12월에 두 개의 주요 투자자 회의에 참여할 예정입니다. 회사는 Piper Sandler 36th Annual Healthcare Conference 에서 오전 11시 ET와 Evercore ISI 7th Annual HealthCONx Conference 에서 오후 4시 15분 ET에 발표를 진행합니다. 두 회의 모두 2024년 12월 3일에 열립니다.
경영진은 두 행사에서 비공식적인 대화를 이끌고 일대일 회의에 참여할 것입니다. 발표는 회사의 투자자 관계 웹사이트에서 실시간으로 중계되며, 이후 30일 이상 다시 볼 수 있습니다.
Aligos Therapeutics (Nasdaq: ALGS), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies du foie et virales, a annoncé sa participation à deux grandes conférences des investisseurs ce mois de décembre. L’entreprise présentera à la Piper Sandler 36th Annual Healthcare Conference à 11h00 ET et à la Evercore ISI 7th Annual HealthCONx Conference à 16h15 ET, toutes les deux le 3 décembre 2024.
La direction animera des discussions informelles lors des deux événements et participera à des réunions individuelles. Les présentations seront diffusées en direct sur le site Web des relations investisseurs de l’entreprise, avec des rediffusions disponibles pendant au moins 30 jours après.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Leber- und Viruskrankheiten spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember bekannt gegeben. Das Unternehmen wird um 11:00 Uhr ET auf der Piper Sandler 36th Annual Healthcare Conference und um 16:15 Uhr ET auf der Evercore ISI 7th Annual HealthCONx Conference präsentieren, beide am 3. Dezember 2024.
Das Management wird bei beiden Veranstaltungen informelle Gespräche führen und an Einzelgesprächen teilnehmen. Die Präsentationen werden live auf der Investor-Relations-Website des Unternehmens übertragen, mit Wiederholungen, die für mindestens 30 Tage danach verfügbar sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two investor conferences being webcast in December:
- Piper Sandler 36th Annual Healthcare Conference
- Fireside Chat at 11:00am ET/8:00am PT on December 3, 2024
- Evercore ISI 7th Annual HealthCONx Conference
- Fireside Chat at 4:15pm ET/1:15pm PT on December 3, 2024
In addition to the presentations, management will participate in one-on-one meetings. A live webcast of each event will be accessible by visiting the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcasts will be available following the presentation for at least 30 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
When is Aligos Therapeutics (ALGS) presenting at the Piper Sandler Healthcare Conference in December 2024?
What time is Aligos Therapeutics (ALGS) presenting at the Evercore ISI HealthCONx Conference?
How long will the webcasts of Aligos Therapeutics (ALGS) December 2024 investor presentations be available?
Where can investors watch Aligos Therapeutics (ALGS) December 2024 conference presentations?
